



28 October 2016

ASX ANNOUNCEMENT

MVP signs major deal with CSIRO on exclusive rights for some key drugs

Medical Developments International Limited (ASX: MVP) is delighted to announce it has signed a Term Sheet with Australia's preeminent science and research body the Commonwealth Scientific and Industrial Research Organisation (CSIRO), to conduct a Research and Development program into new manufacturing technologies for pharmaceutical products. Final documentation is expected to be completed by 31 December 2016.

Chief Executive Officer of MVP, Mr John Sharman, said: "We are delighted to extend our partnership with the CSIRO to develop the next generation of manufacturing technology for pharmaceuticals. We are focusing our efforts on a number of very large pharmaceutical therapeutic markets where we hope to manufacture existing pharmaceutical products for a fraction of the price. If successful, we expect the suite of manufacturing technologies created to be extremely valuable."

Mr Sharman said: "We will use the knowledge gained from the development of our new "Pentrox manufacturing technology" to create patentable intellectual property which will be owned by MVP. Our R&D program is very focused and structured and we expect it to show results within two years."

Director of CSIRO Biomedical Manufacturing Group, Dr Paul Savage, said: "CSIRO is delighted to partner with Medical Developments International to develop this new technology. We have already proven our case in terms of the manufacturing technology for Pentrox. We are confident it can be extended to other medical products and that, with sufficient resources, our partnership with MVP can develop new technologies relating to some of the largest pharmaceutical products in the world."

"If we're successful, CSIRO stands to generate significant royalty revenue through its partnership with MVP. We're also delighted to contribute to MVP's growth strategy and the new manufacturing jobs it could create in the Australian biotech industry."

For more information, please do not hesitate to contact Mr. John Sharman or Mr. David Williams.

Enquiries:

John Sharman
Chief Executive Officer
Medical Developments International Ltd
03 9547 1888

David Williams
Chairman
Medical Developments International Ltd
0414 383 593



About Pentrox

Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used safely and effectively for more than 30 years in Australia with in excess of 6.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Force, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

About CSIRO

The Commonwealth Scientific and Industrial Research Organisation (CSIRO), work to shape the future. CSIRO does this by using science to solve real issues. Our research makes a difference to people, industry and the planet. CSIRO aim to innovate for tomorrow and help improve today – for our customers, all Australians and the world.

The CSIRO Biomedical Manufacturing Group work with biomedical companies to deliver new medical treatments and technologies that benefit millions of people in Australia and overseas, helping them live longer, healthier and more productive lives.